Biblio

Export 22 results:
Tekijä [ Otsikko(Desc)] Tyyppi Vuosi
Suodattimet: First Letter Of Last Name is H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, ym.. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J [Internet]. 2002;16(9):1041 - 9. http://view.ncbi.nlm.nih.gov/pubmed/12087065PDF icon Anne Saaristo et al., FASEB Journal 2002 (966.08 KB)
C
Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, ym.. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes Dev [Internet]. 2010;24(9):875 - 80. http://view.ncbi.nlm.nih.gov/pubmed/20439428PDF icon Pipsa Saharinen et al., Genes & Development 2010 (1.2 MB)PDF icon Pipsa Saharinen et al., Genes & Development 2010, supplement (9.15 MB)
D
Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, ym.. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733PDF icon Tuomas Tammela et al., Circulation Research 2007 (1.1 MB)
E
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, ym.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, ym.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, ym.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
F
Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, ym.. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J [Internet]. 2006;20(9):1462 - 72. http://view.ncbi.nlm.nih.gov/pubmed/16816121PDF icon Terhi Kärpänen et al., FASEB Journal 2006 (2.51 MB)
I
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, ym.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, ym.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, ym.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
O
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, ym.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF icon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF icon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, ym.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF icon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF icon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
P
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, ym.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF icon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
S
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, ym.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
T
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, ym.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, ym.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
V
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, ym.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, ym.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, ym.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, ym.. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646PDF icon Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB)PDF icon Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB)PDF icon Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, ym.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, ym.. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J [Internet]. 2001;20(4):672 - 82. http://view.ncbi.nlm.nih.gov/pubmed/11179212PDF icon Stefano Mandriota et al., EMBO Journal 2001 (736.96 KB)